PharmaResearch Co., Ltd. (214450.KQ)
KRW 259500.0
(2.77%)
KRW 259500.0
(2.77%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 73.08 Billion KRW | -31.31% |
| 2022 | 106.39 Billion KRW | 7.16% |
| 2021 | 99.28 Billion KRW | 79.16% |
| 2020 | 55.42 Billion KRW | 33.54% |
| 2019 | 41.5 Billion KRW | 5.56% |
| 2018 | 39.31 Billion KRW | 350.83% |
| 2017 | 8.72 Billion KRW | 0.57% |
| 2016 | 8.67 Billion KRW | -36.68% |
| 2015 | 13.69 Billion KRW | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 107.85 Billion KRW | 47.57% |
| 2024 Q2 | 93.17 Billion KRW | -13.61% |
| 2023 FY | 73.08 Billion KRW | -31.31% |
| 2023 Q2 | 88.27 Billion KRW | -17.89% |
| 2023 Q1 | 107.51 Billion KRW | 1.05% |
| 2023 Q3 | 90.17 Billion KRW | 2.15% |
| 2023 Q4 | 73.08 Billion KRW | -18.95% |
| 2022 Q3 | 103.19 Billion KRW | 4.08% |
| 2022 Q4 | 106.39 Billion KRW | 3.1% |
| 2022 FY | 106.39 Billion KRW | 7.16% |
| 2022 Q2 | 99.15 Billion KRW | -5.96% |
| 2022 Q1 | 105.43 Billion KRW | 6.19% |
| 2021 FY | 99.28 Billion KRW | 79.16% |
| 2021 Q1 | 50.06 Billion KRW | -9.66% |
| 2021 Q4 | 99.28 Billion KRW | 88.36% |
| 2021 Q3 | 52.71 Billion KRW | 15.62% |
| 2021 Q2 | 45.58 Billion KRW | -8.94% |
| 2020 Q3 | 60.25 Billion KRW | 39.52% |
| 2020 FY | 55.42 Billion KRW | 33.54% |
| 2020 Q4 | 55.42 Billion KRW | -8.02% |
| 2020 Q1 | 41.69 Billion KRW | 0.47% |
| 2020 Q2 | 43.18 Billion KRW | 3.57% |
| 2019 Q3 | 38.73 Billion KRW | 1.58% |
| 2019 FY | 41.5 Billion KRW | 5.56% |
| 2019 Q4 | 41.5 Billion KRW | 7.15% |
| 2019 Q2 | 38.12 Billion KRW | -5.05% |
| 2019 Q1 | 40.15 Billion KRW | 2.14% |
| 2018 Q1 | 43.24 Billion KRW | 530.13% |
| 2018 FY | 39.31 Billion KRW | 350.83% |
| 2018 Q4 | 39.31 Billion KRW | -10.19% |
| 2018 Q3 | 43.77 Billion KRW | -2.62% |
| 2018 Q2 | 44.95 Billion KRW | 3.95% |
| 2017 Q3 | 10.59 Billion KRW | 57.16% |
| 2017 Q2 | 6.74 Billion KRW | -36.3% |
| 2017 Q1 | 10.58 Billion KRW | 70.52% |
| 2017 Q4 | 6.86 Billion KRW | -35.23% |
| 2017 FY | 8.72 Billion KRW | 0.57% |
| 2016 Q3 | 7.48 Billion KRW | 0.0% |
| 2016 Q1 | - KRW | -100.0% |
| 2016 Q4 | 6.2 Billion KRW | -17.11% |
| 2016 FY | 8.67 Billion KRW | -36.68% |
| 2015 FY | 13.69 Billion KRW | 0.0% |
| 2015 Q4 | 12.55 Billion KRW | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| HLB Co., Ltd. | 169.47 Billion KRW | 56.875% |
| iNtRON Biotechnology, Inc. | 1.88 Billion KRW | -3786.836% |
| BINEX Co., Ltd. | 75.68 Billion KRW | 3.435% |
| Bioneer Corporation | 80.61 Billion KRW | 9.334% |
| Anterogen.Co.,Ltd. | 19.98 Billion KRW | -265.675% |
| MEDIPOST Co., Ltd. | 135.73 Billion KRW | 46.155% |
| CrystalGenomics, Inc. | 97.82 Billion USD | 25.287% |
| Helixmith Co., Ltd | 73.55 Billion KRW | 0.64% |
| Chabiotech Co.,Ltd. | 1069.23 Billion KRW | 93.165% |
| Medy-Tox Inc. | 137.14 Billion KRW | 46.707% |
| Peptron, Inc. | 16.36 Billion KRW | -346.495% |
| Amicogen, Inc. | 248.12 Billion KRW | 70.544% |
| Genexine, Inc. | 79.68 Billion KRW | 8.278% |
| HLB Therapeutics Co.,Ltd. | 29.27 Billion KRW | -149.647% |
| LegoChem Biosciences, Inc. | 41.28 Billion KRW | -77.047% |
| ALTEOGEN Inc. | 108.25 Billion KRW | 32.489% |
| SillaJen, Inc. | 19.4 Billion KRW | -276.717% |
| JETEMA, Co., Ltd. | 179.09 Billion KRW | 59.19% |
| OliX Pharmaceuticals,Inc | 52.48 Billion KRW | -39.241% |
| Genomictree Inc. | 7.81 Billion KRW | -835.537% |
| MedPacto, Inc. | 9.56 Billion KRW | -664.047% |
| D&D Pharmatech | 23.98 Billion KRW | -204.71% |
| EASY BIO,Inc. | 105.86 Billion KRW | 30.965% |
| GI Innovation, Inc. | 9.63 Billion KRW | -658.459% |